Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma
- 7 December 2000
- journal article
- Published by Springer Nature in Oncogene
- Vol. 19 (52) , 6015-6022
- https://doi.org/10.1038/sj.onc.1204018
Abstract
The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-CHOP fusion gene. We previously developed a mouse model of liposarcoma by expressing FUS-CHOP in murine mesenchymal stem cells. In order to understand how FUS-CHOP can initiate liposarcoma, we have now generated transgenic mice expressing altered forms of the FUS-CHOP protein. Transgenic mice expressing high levels of CHOP, which lacks the FUS domain, do not develop any tumor despite its tumorigenicity in vitro and widespread activity of the EF1alpha promoter. These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with FUS-CHOP. On the contrary, transgenic mice expressing the altered form of FUS-CHOP created by the in frame fusion of the FUS domain to the carboxy end of CHOP (CHOP-FUS) developed liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1alpha promoter. The characteristics of the liposarcomas arising in the CHOP-FUS mice were very similar to those previously observed in our FUS-CHOP transgenic mice indicating that the FUS domain is required not only for transformation but also influences the phenotype of the tumor cells. These results provide evidence that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma.Keywords
This publication has 23 references indexed in Scilit:
- The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic miceOncogene, 2000
- Human Translocation Liposarcoma-CCAAT/Enhancer Binding Protein (C/EBP) Homologous Protein (TLS-CHOP) Oncoprotein Prevents Adipocyte Differentiation by Directly Interfering with C/EBPβ FunctionPublished by Elsevier ,1998
- CONSEQUENCES OF CHROMOSOMAL ABNORMALITIES IN TUMOR DEVELOPMENTAnnual Review of Genetics, 1997
- Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUSGenomics, 1996
- Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22)Genes, Chromosomes and Cancer, 1994
- A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.Genes & Development, 1994
- Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcomaNature Genetics, 1993
- Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcomaNature, 1993
- CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription.Genes & Development, 1992
- The prognostic value of histologic subtypes in primary extremity liposarcomaCancer, 1989